trending Market Intelligence /marketintelligence/en/news-insights/trending/RMcL5ffylDAE6PkoBc63ow2 content esgSubNav
In This List

Mitsubishi Tanabe to cancel licensing agreement with Kolon Life Science

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Mitsubishi Tanabe to cancel licensing agreement with Kolon Life Science

Mitsubishi Tanabe Pharma Corp. is looking to cancel a licensing agreement signed with Kolon Life Science Inc.

Mitsubishi Tanabe had been planning to acquire exclusive development and commercialization of Kolon's cell therapy Invossa, used for the treatment of knee osteoarthritis. Kolon would have received an upfront payment of ¥2.5 billion with future development and milestone payments and royalties on future sales.

Mitsubishi Tanabe has started negotiations with the Korea-based Kolon for the cancellation of the agreement and will provide the financial impact of the decision at a later date.

As of Dec. 19, US$1 was equivalent to ¥112.98.